Abstract -Symptoms of mycotoxicosis are a result of interactions of mycotoxins with functional molecules and subcellular organelles in the animal cell. The biological effects vary mainly according to the diversity in chemical structures of the mycotoxins, but also because of biological, nutritional and environmental factors. For a few mycotoxins, especially aflatoxin B1, so many effects on biochemical systems have been described that only a fraction could be discussed here. Many of these effects are probably secondary to one and the same primary mechanism of action, others occur at such high concentrations that they will never happen in nature. It is striking that so many mycotoxins act on the DNA-RNA level. In most cases this gives rise to consequences on many levels and with pathological pictures caused by many co-operating factors. Less frequently, the effects are as specific as the inhibition of phosphoenolpyruvate carboxykinase by ochratoxin A. Thus no generalized mechanism can apply to all mycotoxins -not even for one and the same mycotoxin in different circumstances. The mechanism of action for a mycotoxin in mammalian cells may not be applicable to plants and microorganisms if metabolic activation is involved. Despite the many data accumulated so far, some of which have been accounted for in this review, the specific lesions responsible for the acute toxicity of many mycotoxins have not yet been identified. Much work therefore remains to be done in order to fully understand their mechanism of action.
INTRODUCTION
The diversity of animal and human diseases attributable to mycotoxins (mycotoxicoses) is due to the wide variety of chemical structures of the causative mycotoxins. The various biological effects of mycotoxins are attributed largely to the alteration of basic metabolic processes. Acutely affected processes are carbohydrate metabolism, mitochondrial functions, lipid and steroid metabolism and the biosynthesis of proteins and nucleic acids.
By understanding the mechanism of action of the mycotoxins on these processes it may ultimately be possible to develop PROTEINS methods for the control and prevention of mycotoxin problems. By means of a figure ( Fig. 1 ) the major sites of mycotoxin action on RNA and protein synthesis can be indicated. Thus the primary mechanism of action of a mycotoxin may be to modify the DNA template, to impair the transcription process, or inhibit the translation process in protein synthesis. In certain cases the mycotoxin reacts directly with the enzyme protein or coenzyme. All these primary events may lead to secondary effects in terms of modified enzyme activities and, hence, changes in metabolic activity and regulation.
Effects on the DNA level At least 14 mycotoxins are known in the laboratory to be carcinogens, including several aflatoxins, sterigmatocystin, cyclochlorotine, griseofulvin, and patulin. With the exception of cyclochlorotine they are all active on the DNA level (ref. 4).
Two types of interaction have been shown to occur between aflatoxins and nucleic acids. One is a non-covalent, weak and reversal binding (ref. 9), the other is an irreversible covalent binding requiring mammalian metabolizing systems (Fig. 2) . Most of the carcinogenic and genetic activities of aflatoxins and related compounds such as sterigmatocystin have been observed with metabolically activated mycotoxins. Crucial for the covalent binding is the C -C unsaturated bond, which means that aflatoxins B1 and C1 are more active tan3B2 and C2. was due primarily to reduction of thymidine transport into the cell and not to decreased DNA template activity. However, as normal cells do not need external thymidine -they synthesize their own thymidine from uridine -the significance of this transport for the mechanism by which aflatoxins inhibit nucleic acids in normal cells may be questioned.
Recent work by Niranjan et al. showed that aflatoxin Bi administered to experimental animals is covalently linked to liver mitochondria more efficiently than to nuclear DNA. The concentration of carcinogenic adducts in mitochondrial DNA remains unchanged even after 24 hours, possibly because of lack of excision repair. In consequence, mitochondrial transcription and translation remain inhibited for up to 24 hours. The authors suggest that this longterm inhibition of mitochondrial biosynthetic processes and possible mitochondrial mutational events may contribute to the carcinogenic process. In view of the large number of mitochondria per cell, this hypothesis is obviously open to certain objections.
There are several structural similarities between aflatoxin B1 and sterigmatocystin, e.g. the dimensions and absolute configuration of the bisdihydrofuran moiety are very similar (ref. 16 ). This suggests a metabolic activation on the same site, the C -C double bound, as in aflatoxin B1. Experimental data support this (re. 7). The mycotoxins may therefore operate by a common biochemical mechanism. Thus inhibition of DNA and RNA synthesis should be one of the primary modes of sterigmatocystin action.
A direct interaction of patulin and penicillic acid with cellular DNA has been consistently observed in appropriate bacterial and mammalian cell systems. Single-and double-strand breaks were induced by both toxins in HeLa and mammary carcinoma cell DNA (ref. 18, 19) . An approximately fourfold larger total dose of penicillic acid was used to achieve carcinogenic effects in rats and mice, similar to those obtained with patulin (ref. 20, 21).
Even for another group of mycotoxins, the psoralens (furocoumarins), it is now apparent that they can react with DNA (photoreaction) which is very likely the primary mechanism by which these compounds function. There are no prerequirements for prior metabolic activation of the psoralens. The mechanism by which psoralens form adducts with DNA proceeds in three steps -one which can proceed in the dark, the other two by absorption of quanta of radiant energy (ref. EFFECT ON RNA POLYMERASE One prominent effect of aflatoxin B administration to an animal is the decrease in RNA content and in RNA polymerase in the nuclei of the liver (ref.
9, 33-36). Aflatoxin Bi was about three times as active as G , whereas B2 had no effect at all (ref. 37), which led to the conclusion that the 2,3 unsaturated double bond in the dihydrofurfuran moiety was important for activity.
Other mycotoxins with a similar mechanism of action are a-amanitin (ref. have not been found to inhibit in vivo synthesis.
CH2
Polysome disaggregation may be the mechanism by I which aflatoxin B1 disrupts protein synthesis. R3
The simultaneously formed monosomes lack RNA and peptidyl-tRNA and contain only low levels of tRNA (ref.
65).
Recently, ochratoxin A has also been included in the group of mycotoxins acting on the translation level. The mycotoxin acts by degrading the mRNA coding for the phosphoenolpyruvate carboxykinase in the kidney (ref. 66) . Furthermore it has been established why ochratoxin A (but not ochratoxin a) is toxic. It was found that ochratoxin A may act as an analogue of phenylalanine as regards aminoacylation of tRNA in bacteria (ref. 67, 68) . This reaction is catalysed by phenylalanyl-tRNA synthetase and is fundamental for all living organisms. Ochratoxin A competitively inhibits the formation of phenylalanyltRNA. The affinity of the phenylalanyl-tRNA synthetase for ochratoxin A was, however, about one-threehundredth of that of phenylalanine and the question then came up as to how ochratoxin A toxicity arises in intact animal cells. Part of the answer is, according to Creppy et al. (ref. 69, 70) that the mammalien synthetase has a high affinity for ochratoxin A and a low affinity for phenylalanine. Another contributory factor may be that ochratoxin A and its metabolites, some of which are still toxic, accumulate inside cells (ref. 
INHIBITION BY MYCOTOXINS OF KEY ENZYMES IN METABOLIC PROCESSES
Major biochemical effects of mycotoxins involve the modification of normal metabolic and other vital processes. The mode of their action appears to be based primarily on their ability to interact with macromolecules, subcellular organelles and organs. Many of these mycotoxin-induced effects may be derived from and secondary to their disruption of nucleic acid or protein synthesis.
Carbohydrate metabolism The effect of mycotoxins on carbohydrate metabolism is generally discerned as reduced hepatic glycogen and increased blood glucose levels. Mycotoxins that can cause these effects are aflatoxins, ochratoxin A, rubratoxin B, cyclochlorotine and citreoviridin.
Aflatoxin B , cyclochlorotine and citreoviridin all decrease the liver glycogen level, y inhibiting biosynthetic enzymes such as glycogen synthetase and by increasing the activity of enzymes metabolizing glycogen precursors, e.g. the NADP-reducing enzyme glucose 6-phosphate dehydrogenase (ref. 72, 73) .
In their study, Shankaran et al. (ref. 72) injected 2.7 mg aflatoxin B1in oneday-old chicks and noted, besides the above-mentioned effects, also decreased activities of glycogen phosphorylase, phosphoglucomutase and glucose 6-phosphatase. It is difficult, however, to forecast how these effects may influence the glycogen level, as the first two enzymes mentioned catalyse glycogen breakdown and the third enzyme, glucose 6-phosphatase, catalyses glucose 6-phosphate elimination. These contradictory results were probably secondary effects, as neither aflatoxin B1 nor its metabolites inhibited the enzymes involved in glycogen metabolism in vitro (ref.
72).
Ochratoxin A is another mycotoxin which decreases liver glycogen (ref. 74, 75) . Especially in adrenalectomized rats, liver glycogen was almost eintirely depleted after ochratoxin A treatment, but this effect could be eliminated by pretreating with hydrocortisone, suggesting an interaction of ochratoxin A with hormone balance mechanisms (ref. 74 ).
Pitout (ref. 76 ) described an inhibition of the phosphorylase system by ochratoxin A. However, as no single enzyme in this system was inhibited by the toxin, Pitout suggested that the protein kinase B activation by cAMP might be impaired. Heller and Rbschenthaler (ref. 77) found that ochratoxin A competitively inhibited cAMP binding to bovine receptor protein, but only at very high concentrations.
In 1979 Meisner and Selanik (ref. 78) found that ochratoxin A, at comparatively low concentrations (2 mg/kg per day for 2 days), selectively decreased gluconeogenesis in kidney slices by depressing phosphoenolpyruvate carboxykinase activity by 50%. This enzyme is a link between the citric acid cycle and gluconeogenesis and makes possible transformation of citric acid cycle intermediates and their precursors via oxaloacetate -phosphoenolpyruvate into glycogen (Fig. 4) . Recently, Meisner et al. (ref. 80) showed that this effect of ochratoxin A was caused by a decrease in the concentration of the mRNA coding for the phosphoenolpyruvate carboxykinase in the kidney rather than by an inhibition of the enzyme itself. There was no effect on transcript ion. 
